Ishaq Syed Muhammad, Kehar Shahnaz Imdad, Zafar Shahid, Hasan Syed Furqan Ul
Dr. Syed Muhammad Ishaque, MBBS, M.Phil, Consultant Pathologist, Bolan Medical Complex & Sandeman Provincial Hospital, Quetta. Pakistan.
Dr. Shahnaz Imdad Kehar, MBBS, M.Phil, Associate Professor, Department of Pathology, BMSI, JPMC, Karachi, Pakistan.
Pak J Med Sci. 2016 Jan-Feb;32(1):160-4. doi: 10.12669/pjms.321.8828.
Correlation of CD24 expression with histological grading and TNM staging of retinoblastoma.
This cross-sectional study was conducted in the Department of Pathology, BMSI, JPMC and NICH from 1(st) January 2009 to 31(st) December 2013. A total 68 diagnosed cases of retinoblastoma were selected for CD24 immuno staining. The data was analyzed by using SPSS version 22.
Out of 68 cases 7.35% showed grade 1 followed by 11.76% in G2, 26.47% in G3 and 54.41% in G4. Majority of cases i.e. 60.29% in stage IV followed by 19.11% in stage I, 10.29% each in stage II and stage III. CD24 immuno staining positivity was seen in majority of grade 3 and grade 4. In grade 3, 38.88% showed moderate and 22.22% strong immuno reaction. Amongst grade 4, 40.54% showed moderate and 13.51% strong positive. Variable immuno pattern was observed according to TNM staging. In stage I, 46.15% showed moderate and 7.69% strong positivity, while in stage II, 57.14% were negative for saining. In stage III, 42.85% were negative while 28.57% each showed moderate and strong staining. Majority of cases in stage IV i.e. 48.78% were negative for staining while 34.14%, 17.07% showed moderate and severe CD24 immuno staining.
Majority of grade I retinoblastoma were in TNM stage I & II and mostly were immuno negative. Lymph node and distant metastatic cases were 75% in G4 and 25% in G3, all of them showed moderate to strong immunoreactivity. These results showed that CD24 expression may be a marker of poor prognosis in retinoblastoma. Whereas TNM staging of retinoblastomas with CD24 expression had varying pattern and showed no significant correlation between them.
探讨视网膜母细胞瘤中CD24表达与组织学分级及TNM分期的相关性。
本横断面研究于2009年1月1日至2013年12月31日在孟买圣乔治医院、卡拉奇真纳医学院病理科及国家儿童健康研究所开展。共选取68例经诊断的视网膜母细胞瘤病例进行CD24免疫染色。数据采用SPSS 22.0软件进行分析。
68例病例中,7.35%为1级,2级占11.76%,3级占26.47%,4级占54.41%。大多数病例处于IV期,占60.29%,其次是I期,占19.11%,II期和III期各占10.29%。大多数3级和4级病例可见CD24免疫染色阳性。在3级中,38.88%呈中度免疫反应,22.22%呈强免疫反应。在4级中,40.54%呈中度阳性,13.51%呈强阳性。根据TNM分期观察到不同的免疫模式。在I期,46.15%呈中度阳性,7.69%呈强阳性;而在II期,57.14%染色阴性。在III期,42.85%染色阴性,28.57%各呈中度和强染色。IV期大多数病例(48.78%)染色阴性,而34.14%、17.07%呈中度和重度CD24免疫染色。
大多数I级视网膜母细胞瘤处于TNM I期和II期,大多免疫阴性。G4期淋巴结及远处转移病例占75%,G3期占25%,均表现为中度至强免疫反应。这些结果表明,CD24表达可能是视网膜母细胞瘤预后不良的一个标志物。而伴有CD24表达的视网膜母细胞瘤的TNM分期具有不同模式,两者之间无显著相关性。